Clinical and Laboratory Profile of Myasthenia Gravis in Children At Sohag University Hospitals
NCT06774937 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 20
Last updated 2025-01-14
Summary
This study includes clinical and laboratory studies of patients with Myathenia gravis at Sohag Neurology outpatient clinic of pediatric department
Conditions
- Myasthenia Gravis in Children
Interventions
- DIAGNOSTIC_TEST
-
All patients in this study were subjected to the followings: (A) Clinical history focusing on: Sociodemographic data: age, gender , residence,and degree of consanguinity. Full neurodevelopmental his
Thorough clinical examination: 1\. General examination including general look, vital signs and anthropometric measurements. 2\. Scale system include gross motor function and muscle power(Quantitative Myasthenia Gravis Scale) \[36\] 3. detailed neurological examination including motor ,sensory and reflexes. (C) Investigations: 1. Electrophysiological testing: EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes. NCS: including repetitive nerve stimulation test (r NST) 2. laboratory studies: * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS. * Thyroid function tests : 3. Imaging: • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed. 4. molecular studies (when possible).
- DIAGNOSTIC_TEST
-
EMG ,rNST,Ach R antibodies & thyroid function
C) Investigations: 1. Electrophysiological testing: EMG : is especially useful in diagnosis of seronegative MG and congenital myasthenic syndromes. NCS: including repetitive nerve stimulation test (r NST) 2. laboratory studies: * Serology. Detection of antibodies to the AChR supports the diagnosis of JMG. In young children where AChR antibodies are negative this can lead to difficulty in differentiating from CMS. * Thyroid function tests : 3. Imaging: • CT chest: Although thymoma in children is rare, the thymus must be imaged once JMG has been diagnosed. 4. molecular studies (when possible).
Sponsors & Collaborators
-
Sohag University
lead OTHER
Eligibility
- Min Age
- 1 Month
- Max Age
- 16 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-02-01
- Primary Completion
- 2025-05-01
- Completion
- 2025-08-01
Countries
- Egypt
Study Locations
More Related Trials
-
A Prospective Cohort Study Of Myasthenia Gravis
NCT04674605 ·Status: UNKNOWN
-
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT06617741 ·Status: RECRUITING
-
Interleukin and Autoantibodies in Myasthenia Gravis.
NCT05301153 ·Status: UNKNOWN
-
Myasthenia Gravis Registry in China
NCT06241521 ·Status: RECRUITING
-
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
NCT06392386 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
NCT05374590 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2/PHASE3
-
Construction of A Multimodal Digital Assessment Model for Myasthenia Gravis
NCT07146425 ·Status: RECRUITING
-
Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis
NCT00515450 ·Status: COMPLETED ·Phase: PHASE3
-
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
NCT05408702 ·Status: COMPLETED
-
Expediting Myasthenia Gravis (MG) Diagnostic Evaluation: A Novel, Proof-of-Concept for Undiagnosed, Symptomatic Patients That Uses Social Media Targeting and Self-Assessment
NCT06381284 ·Status: COMPLETED
-
The Specificity, Sensitivity and Clinical Correlation of CBA, RIPA and ELISA in Detecting AChR and MuSK IgG of Myasthenia Gravis
NCT05219097 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT02965573 ·Status: COMPLETED ·Phase: PHASE2
-
TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study
NCT04182984 ·Status: RECRUITING
-
Randomized Study of Intravenous Immunoglobulin in Patients With Mild or Moderate Myasthenia Gravis
NCT00004682 ·Status: TERMINATED ·Phase: NA
-
Acupuncture in Myasthenia Gravis (AcuMG)
NCT05230082 ·Status: COMPLETED ·Phase: NA
-
Burden of Disease in Myasthenia Gravis
NCT03979521 ·Status: COMPLETED
-
Therapeutic Plasma Exchange in MG
NCT01927692 ·Status: COMPLETED
-
OVEMP in Myasthenia
NCT03049956 ·Status: COMPLETED ·Phase: NA
-
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT05067348 ·Status: RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis
NCT02473952 ·Status: COMPLETED ·Phase: PHASE2
-
An Early Exploratory Clinical Study of GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis
NCT06759948 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
NCT03669588 ·Status: COMPLETED ·Phase: PHASE3
-
The EXPLORE MG Registry for Myasthenia Gravis
NCT03792659 ·Status: RECRUITING
-
Validation and Scaling of Screening Program for Undiagnosed Myasthenia Gravis-Social Media Campaign Paired With a Self-moderated Assessment
NCT06866483 ·Status: RECRUITING
-
Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
NCT04590716 ·Status: COMPLETED